Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?
Approximately one-third of patients with schizophrenia do not receive meaningful benefits from first-line antipsychotics (1). When this occurs despite two or more adequate treatment episodes with different antipsychotics, it is termed treatment-resistant schizophrenia (1). Treatment-resistant schizophrenia is associated with reduced quality of life and substantial economic cost to the individual and society (2). Clozapine is the only licensed medication for treatment-resistant schizophrenia, and early
